

1. Identification

1.1. Product identifier

Product Identity Helixate FS
Alternate Names Helixate FS

1.2. Relevant identified uses of the substance or mixture and uses advised against

Intended use See Technical Data Sheet.
Application Method See Technical Data Sheet.

1.3. Details of the supplier of the safety data sheet

Company Name CSL Behring L.L.C.
 1020 First Avenue
 PO Box 61501
 King of Prussia, PA

Emergency

24 hour Emergency Telephone No. Emergency Response: (800) 424-9300
 Emergency Product Information: (800) 504-5434
Customer Service: CSL Behring L.L.C. (610) 878-4000

2. Hazard(s) identification

2.1. Classification of the substance or mixture

No applicable GHS categories.

2.2. Label elements

Using the Toxicity Data listed in section 11 and 12 the product is labeled as follows.

No applicable GHS categories.

[Prevention]:

No GHS prevention statements

[Response]:

No GHS response statements

[Storage]:

No GHS storage statements

[Disposal]:

No GHS disposal statements

3. Composition/information on ingredients

This product contains the following substances that present a hazard within the meaning of the relevant State and Federal Hazardous Substances regulations.

Ingredient/Chemical Designations	Weight %	GHS Classification	Notes
Sucrose CAS Number: 0000057-50-1	1.0 - 10	Not Classified	[1][2]

[1] Substance classified with a health or environmental hazard.

[2] Substance with a workplace exposure limit.

[3] PBT-substance or vPvB-substance.

*The full texts of the phrases are shown in Section 16.

Non Hazardous Ingredients:

- Antihemophilic Factor (Recombinant), Active ingredient
- Sucrose, USP (0.9-1.3%), (57-50-1), Stabilizer
- Calcium Chloride, USP (2-3 mM), (10043-52-4), Osmotic balance adjustment
- Sodium (27-36 mEq/L), Osmotic balance adjustment
- Chloride (32-40 mEq/L), Osmotic balance adjustment
- Glycine, USP (21-25 mg/mL), (56-40-6), Stabilizer
- Histidine, USP (18-23mM), (7006-35-1), Stabilizer
- Imidazole (<20 ug/1000 IU AHF) (288-32-4) Stabilizer
- Polysorbate-80 (< 35 ug/mL), (9005-65-6), Stabilizer
- Tri-n-butylphosphate (< 5 ug/1000 IU AHF)
- Copper (<0.6 ug/1000 IU AHF)
- Water For Injection, USP, (7732-18-5), Volume adjustment

4. First aid measures

4.1. Description of first aid measures

- | | |
|-------------------|---|
| General | In all cases of doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person. |
| Inhalation | Remove to fresh air, keep patient warm and at rest. If breathing is irregular or stopped, give artificial respiration. If unconscious place in the recovery position and obtain immediate medical attention. Give nothing by mouth. |
| Eyes | Irrigate copiously with clean water for at least 15 minutes, holding the eyelids apart and seek medical attention. |
| Skin | Remove contaminated clothing. Wash skin thoroughly with soap and water or use a recognized skin cleanser. |
| Ingestion | Rinse from mouth and seek medical guidance. Induce vomiting only as directed by medical personnel. Never give anything by mouth to an unconscious person. |

4.2. Most important symptoms and effects, both acute and delayed

Overview **Potential Health Effects:** This product has been prepared from the pooled plasma of healthy adult donors. Each plasma donation has been tested for the absence of antibodies against HIV-1, HIV-2 and Hepatitis C, as well as Hepatitis B surface antigens. In addition, the product underwent a minimum of two different virus reduction procedures. The final fractionation pool used in the manufacture of this product has also been tested for antibodies against HIV-1/HIV-2 and Hepatitis B surface antigen.

Furthermore, only fractionation pools which are nonreactive for HCV RNA, HIV RNA, HAV RNA, and negative for HBV DNA, and high titer Parvovirus B19 DNA by Polymerase Chain Reaction (PCR) Technology are utilized. However, the risk of infectivity due to known or as yet unknown pathogens cannot be totally eliminated from this product.

No adverse health effects anticipated with normal handling and use in appropriate medical setting. Medical implications of therapeutic use are described in product package insert or may be found in the Physicians' Desk Reference.

Emergency Overview: This product is a sterile prescription pharmaceutical. It is to be administered only at the order of a licensed physician. This product is safe when used for its intended purpose and administered as directed by a physician. In addition, no adverse health effects are anticipated as a result of incidental contact or exposure to this product by those handling it or administering it in a therapeutic setting. More detailed information is

available in the product package insert. Please report adverse events in patients using this product to the manufacturer at the telephone number listed above.

Eye/skin contact: No data. No adverse health effects reported nor anticipated.

Skin Absorption: This product is not absorbed through the skin.

Ingestion: Not intended for oral use. Relatively non-toxic if ingested.

Chronic Effects/Carcinogenicity: None known or anticipated under normal handling and exposure conditions.

See section 2 for further details.

5. Fire-fighting measures

5.1. Extinguishing media

Product is not flammable. The only potential fire hazard would involve packaging material.

5.2. Special hazards arising from the substance or mixture

Hazardous decomposition: None known.

5.3. Advice for fire-fighters

Product is not flammable. The only potential fire hazard would involve packaging material.

Packaging material fire may produce carbon monoxide and other gaseous asphyxiants plus airborne particulate matter.

Fire fighting personnel should respond with appropriate protective clothing, firefighting gear, and breathing equipment as trained. All other personnel should exit the area and proceed to a gathering point in an area unaffected by the fire and smoke.

ERG Guide No. ----

6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Put on appropriate personal protective equipment (see section 8).

6.2. Environmental precautions

Use good personal hygiene practices. Wash hands before eating, drinking, smoking or using toilet. Promptly remove soiled clothing and wash thoroughly before reuse.

6.3. Methods and material for containment and cleaning up

Large Spill: Absorb spills with material suitable for aqueous solutions and dispose in solid waste container, or mop spilled material with detergent/water or bleach/water solution and dispose in sanitary sewer. Ventilate area, if desired.
Small Spill: Clean area of spill with wetted toweling and dispose in solid waste container, or follow procedure for large spills.

7. Handling and storage

7.1. Precautions for safe handling

Handle containers carefully to prevent damage and spillage.

7.2. Conditions for safe storage, including any incompatibilities

Incompatible materials: None known.

Store in accordance with the conditions specified in the product package insert.

7.3. Specific end use(s)

No data available.

8. Exposure controls and personal protection

8.1. Control parameters

Exposure

CAS No.	Ingredient	Source	Value
0000057-50-1	Sucrose	OSHA	TWA 15 mg/m3 (total) TWA 5 mg/m3 (resp)
		ACGIH	TWA: 10 mg/m3
		NIOSH	TWA 10 mg/m3 (total) TWA 5 mg/m3 (resp)
		Supplier	No Established Limit

Carcinogen Data

CAS No.	Ingredient	Source	Value
0000057-50-1	Sucrose	OSHA	Select Carcinogen: No
		NTP	Known: No; Suspected: No
		IARC	Group 1: No; Group 2a: No; Group 2b: No; Group 3: No; Group 4: No;

8.2. Exposure controls

Respiratory	None required.
Eyes	None required to provide protection against this product. Eye protection may be required by procedure of administration.
Skin	None required for protection against the product. Medical-grade examination or surgical gloves may be required by procedure of administration.
Engineering Controls	Not Applicable
Other Work Practices	Use good personal hygiene practices. Wash hands before eating, drinking, smoking or using toilet. Promptly remove soiled clothing and wash thoroughly before reuse.

9. Physical and chemical properties

Appearance	Colorless to faint yellow clear aqueous Liquid
Physical Form of Pure Concentrate	Stable, white to off-white powder (lyophilized)
Odor	Unspecified
Odor threshold	Not Measured
pH	6.9 +/- 0.5
Melting point / freezing point	Unspecified
Initial boiling point and boiling range	Unspecified
Flash Point	NA
Evaporation rate (Ether = 1)	Unspecified
Flammability (solid, gas)	Not Applicable
Upper/lower flammability or explosive limits	Lower Explosive Limit: NA Upper Explosive Limit: NA
Vapor pressure (Pa)	Unspecified

Vapor Density	Unspecified
Specific Gravity	Unspecified
Solubility in Water	Complete
Partition coefficient n-octanol/water (Log Kow)	Not Measured
Auto-ignition temperature	NA
Decomposition temperature	Not Measured
Viscosity (cSt)	Not Measured

9.2. Other information

No other relevant information.

10. Stability and reactivity

10.1. Reactivity

Hazardous Polymerization will not occur.

10.2. Chemical stability

Stable under normal circumstances.

10.3. Possibility of hazardous reactions

No data available.

10.4. Conditions to avoid

No data available.

10.5. Incompatible materials

None known.

10.6. Hazardous decomposition products

None known.

11. Toxicological information

Acute toxicity

The pure, lyophilized concentrate of Helixate FS is a sterile, stable, purified, non-pyrogenic, dried powder with biological activity indicated in the treatment of Hemophilia A. When reconstituted into its dose-form for intravenous administration, this product is a sterile, aqueous solution containing recombinant antihemophilic factor, stabilizers, and osmotic agents. It also contains trace amounts of mouse and hamster protein used in the process of manufacturing and purifying the concentrate. It is not expected to be toxic by ingestion or a skin/eye irritant. More comprehensive and detailed product information is contained in the product package insert or may be found in the Physicians' Desk Reference.

Ingredient	Oral LD50, mg/kg	Skin LD50, mg/kg	Inhalation Vapor LD50, mg/L/4hr	Inhalation Dust/Mist LD50, mg/L/4hr	Inhalation Gas LD50, ppm
Sucrose - (57-50-1)	No data available	No data available	No data available	No data available	No data available

Note: When no route specific LD50 data is available for an acute toxin, the converted acute toxicity point estimate was used in the calculation of the product's ATE (Acute Toxicity Estimate).

Classification	Category	Hazard Description
-----------------------	-----------------	---------------------------

Acute toxicity (oral)	---	Not Applicable
Acute toxicity (dermal)	---	Not Applicable
Acute toxicity (inhalation)	---	Not Applicable
Skin corrosion/irritation	---	Not Applicable
Serious eye damage/irritation	---	Not Applicable
Respiratory sensitization	---	Not Applicable
Skin sensitization	---	Not Applicable
Germ cell mutagenicity	---	Not Applicable
Carcinogenicity	---	Not Applicable
Reproductive toxicity	---	Not Applicable
STOT-single exposure	---	Not Applicable
STOT-repeated exposure	---	Not Applicable
Aspiration hazard	---	Not Applicable

12. Ecological information

12.1. Toxicity

No ecological damage or persistence in the environment expected under normal conditions of use or with proper disposal. Environmental fate and transport of this product have not been studied.

Aquatic Ecotoxicity

Ingredient	96 hr LC50 fish, mg/l	48 hr EC50 crustacea, mg/l	ErC50 algae, mg/l
Sucrose - (57-50-1)	Not Available	Not Available	Not Available

12.2. Persistence and degradability

There is no data available on the preparation itself.

12.3. Bioaccumulative potential

Not Measured

12.4. Mobility in soil

No data available.

12.5. Results of PBT and vPvB assessment

This product contains no PBT/vPvB chemicals.

12.6. Other adverse effects

No data available.

13. Disposal considerations

13.1. Waste treatment methods

Observe all federal, state and local regulations when disposing of this substance.

Waste must be disposed in accordance with federal, state and local environmental regulations. Uncontaminated product may be disposed by flushing down the sanitary sewer, or by mixing with a liquid sorbent and then placing mixture in the solid waste container for disposal. Incineration is the preferred method of disposal for any contaminated product.

14. Transport information

	DOT (Domestic Surface Transportation)	IMO / IMDG (Ocean Transportation)	ICAO/IATA
14.1. UN number	Not Applicable	Not Regulated	Not Regulated
14.2. UN proper shipping name	Not Regulated	Not Regulated	Not Regulated
14.3. Transport hazard class(es)	DOT Hazard Class: Not Applicable DOT Label: ---	IMDG: Not Applicable Sub Class: Not Applicable	Air Class: Not Applicable
14.4. Packing group	Not Applicable	Not Applicable	Not Applicable
14.5. Environmental hazards			
IMDG	Marine Pollutant: No		
14.6. Special precautions for user			
	No further information		

15. Regulatory information

Regulatory Overview	The regulatory data in Section 15 is not intended to be all-inclusive, only selected regulations are represented.
Toxic Substance Control Act (TSCA)	All components of this material are either listed or exempt from listing on the TSCA Inventory.
WHMIS Classification	Not Regulated
US EPA Tier II Hazards	Fire: No Sudden Release of Pressure: No Reactive: No Immediate (Acute): No Delayed (Chronic): No
EPCRA 311/312 Chemicals and RQs:	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
EPCRA 302 Extremely Hazardous:	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
EPCRA 313 Toxic Chemicals:	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
Proposition 65 - Carcinogens (>0.0%):	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
Proposition 65 - Developmental Toxins (>0.0%):	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
Proposition 65 - Female Repro Toxins (>0.0%):	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
Proposition 65 - Male Repro Toxins (>0.0%):	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
N.J. RTK Substances (>1%) :	
To the best of our knowledge, there are no chemicals at levels which require reporting under this statute.	
Penn RTK Substances (>1%):	

Sucrose

16. Other information

The information and recommendations contained herein are based upon data believed to be correct. However, no guarantee or warranty of any kind, expressed or implied, is made with respect to the information contained herein. We accept no responsibility and disclaim all liability for any harmful effects which may be caused by exposure to our products. Customers/users of this product must comply with all applicable health and safety laws, regulations, and orders.

The full text of the phrases appearing in section 3 is: Not Applicable

This is the first version in the GHS SDS format. Listings of changes from previous versions in other formats are not applicable.

The information contained herein is based upon data considered true and accurate. CSL Behring makes no warranties, express or implied, as to the adequacy of the information contained herein. This information is offered solely for the user's consideration, investigation, and verification. Report to the manufacturer any allegations of health effects resulting from handling or accidental contact with this material.

End of Document